Teva Coreg Damages Reinstated As AAM Bemoans ‘Antithetical’ Ruling
Israeli Firm Is On Hook Again For $235m Payment
Teva has once again been instructed to compensate GSK with $235m in damages after a split US Court of Appeals reversed a lower court finding that Teva had not willfully induced infringement of a method-of-use patent shielding the originator’s Coreg antihypertensive.
You may also be interested in...
Teva has made good on its stated intention to bring its long-running US legal battle with GSK over “skinny-label” generics to the Supreme Court. In a detailed certiorari petition, the firm sets out its arguments for why the matter warrants review.
Teva will not get a third hearing at the US Court of Appeals for the Federal Circuit in its long-running dispute with GSK over skinny-label generics, after the appeals court rejected a petition for the full bench to re-examine the case.
An induced-infringement attack on Hikma’s skinny-label generic version of Vascepa had been cited as evidence of the potential harm that would be caused by controversial rulings in separate litigation involving GSK and Teva. However, these fears may now appear overstated after the claim against Hikma was dismissed.